During Monday’s trading session, the shares of a research-based Global Pharmaceutical and Biotech company surged nearly 4 percent to Rs. 1,441.95, after its antibiotic drug ‘Zaynich’ achieved 97 percent effectiveness in treating severe pneumonia infections.
With a market capitalisation of Rs. 22,745 crores, at 12:30 p.m., the shares of Wockhardt Limited were trading in the green at Rs. 1,400 on BSE, up by nearly 1 percent, as against its previous closing price of Rs. 1,386.95.
What’s the News
Wockhardt Limited, in its latest regulatory filings with the stock exchanges, announced that Zaynich (Zidebactam/Cefepime, WCK 5222) achieved over 97% clinical efficacy in treating severely ill patients with infections caused by carbapenem-resistant Gram-negative pathogens, including meropenem-resistant strains.
The study employed a distinctive design, encompassing various severe infections such as hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), bloodstream infections (BSI), complicated intra-abdominal infections (cIAI), and complicated urinary tract infections (cUTI).
Zaynich demonstrated an overall clinical efficacy rate of 98% across all indications at the test-of-cure (TOC) assessment, conducted 7–10 days after completing treatment. Specifically, efficacy reached 100% for BSI, HABP/VABP, and cIAI, while cUTI showed a clinical efficacy rate of 97.3%.
The treatment has proven life-saving for more than 100 critically ill patients in India and the U.S., who were suffering from life-threatening extensively drug-resistant (XDR) Gram-negative infections.
The clinical study was conducted across 15 top-tier tertiary care hospitals in India and exclusively included patients with confirmed
carbapenem-resistant infections, identified using advanced molecular diagnostic technologies.
The study, approved by the Drugs Controller General of India (DCGI), highlights Zaynich’s potential as a critical antibiotic for treating carbapenem-resistant infections. Current alternatives, such as colistin and polymyxins, face significant limitations due to toxicity and reduced efficacy.
With antimicrobial resistance posing a global health threat, Zaynich’s ability to target all critical-priority Gram-negative pathogens identified by the U.S. Centers for Disease Control and Prevention (CDC) and the World
Health Organization (WHO) underscores its significance in combating this urgent issue.
About the Drug
Zaynich is Wockhardt’s innovative proprietary antibiotic, combining Zidebactam and Cefepime, designed to combat multi-drug-resistant Gram-negative infections.
It is currently in the final stages of a multinational Phase III study, which aims to support its global registration and marketing authorization.
Previously, several Phase I studies, including clinical pharmacology trials involving Zidebactam and Cefepime, were successfully conducted in the United States.
Also read….
Financials
Wockhardt Limited reported a marginal growth in the revenue from operations, experiencing a rise of nearly 7.4 percent YoY, increasing from Rs. 753 crores in Q2 FY24 to Rs. 809 crores in Q2 FY25.
Similarly, during the same period, the company’s net loss decreased from Rs. 73 crores to Rs. 16 crores, representing a growth of around 78 percent YoY.
Stock Performance
The stock has delivered multibagger returns of nearly 205.3 percent in one year, while around 67 percent of positive returns in the last six months. Likewise, the shares of Wockhardt Limited have given positive returns of about 0.2 percent in the last one month.
About the Company
Wockhardt Limited is a global pharmaceutical and biotech company with a presence in the USA, UK, Switzerland, Ireland, Russia and many other countries. It has manufacturing and research facilities in India, USA & UK and a manufacturing facility in Ireland and Dubai.
Written by Shivani Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
Start Your Stock Market Journey Today!
Want to learn Stock Market trading and Investing? Make sure to check out exclusive Stock Market courses by FinGrad, the learning initiative by Trade Brains. You can enroll in FREE courses and webinars available on FinGrad today and get ahead in your trading career. Join now!!
